As the world's first functional cure for hepatitis B, Bepirovirsen was approved for sale in Japan in August. On September 4, at the Asian Hepatology Summit and HBV Cure Science Conference in Singapore, Professor Hou Jinlin of Southern Medical University revealed for the first time the Chinese population data of the Bepirovirsen Global Phase III study: the functional cure rate of Chinese patients with chronic hepatitis B can reach up to 61%, and the efficacy and safety trends are consistent with global data.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.